Finally, Edward Gane of Auckland City Hospital in New Zealand presented
results from part 2 of SURVEYOR-1, looking at patients without cirrhosis with HCV
genotypes 4, 5 or 6 who were treated with 300mg ABT-493 + 120mg ABT-530 for 12
weeks.
Although HCV genotype 1 is most common
in Europe, North and South America and much of Asia, genotypes 4, 5 and 6 occur
more often in low- and middle-income countries with a high burden of hepatitis
C. Genotype 4 is the predominant type in the Middle East and parts of Africa,
genotype 5 is most common in South Africa and genotype 6 is found in parts of
Asia.
This analysis included 34
patients: 22 with genotype 4, 1 with genotype 5 and 11 with genotype 6. Half
were men, a quarter were Asian, the median age was 55 years, 15% were
treatment-experienced and 15% had advanced fibrosis.
The SVR12 rate was 100% for all
these less extensively studied genotypes. Treatment was safe and well tolerated,
with no serious adverse events, grade 2 or higher laboratory abnormalities, or
discontinuations for this reason.
Based on these findings from
SURVEYOR-1 and SURVEYOR-2, phase 3 studies are now evaluating ABT-493 plus
ABT-530 for 8 or 12 weeks in a larger number of patients with all six major HCV
genotypes, with and without cirrhosis.